Patients with advanced NSCLC receiving anti‐PD‐1/anti‐PD‐L1 therapy in the second line have a favorable association between the gut's Akkermansiaceae and the disease's stability and immunotherapy response. Here, CD274 is linked to non-small cell lung carcinoma.